ENOblock synergizes with colistin to treat Acinetobacter baumannii infections
Year: 2025
Type: article
Abstract: High-throughput screening studies provide an additional approach to discovering repurposed drugs for antimicrobial treatments. In this work, we report the identification of ENOblock, an anticancer drug, as an antimicrobial agent. We computationally and experimentally validated that ENOblock synergizes with colistin, the last resort antibiotic. Additionally, we identified enolase as the potential bacterial target for ENOblock. The in silico and in vitro antibacterial activity of ENOblock translated into potent in vivo efficacy in an animal infection model. Collectively, the preclinical data support the selection of ENOblock as a promising candidate for antimicrobial development, with the potential to address the urgent threat of infections caused by Acinetobacter baumannii.
Source: EMBO Molecular Medicine
Authors: Irene Molina Panadero, Antonio Moreno Rodríguez, Angela Rey Hidalgo, Mercedes de la Cruz, Pilar Sánchez, Laura Tomás Gallardo, Thanadon Samernate, Milan Sencanski, Sanja Glisic, Olga Genilloud, Poochit Nonejuie, Antonio J Pérez-Pulido, Abdelkrim Hmadcha, Younes Smani
Institutions: Consejo Superior de Investigaciones Científicas, Centro Andaluz de Biología del Desarrollo, Universidad Pablo de Olavide, Fundación Medina, Parque Tecnológico de la Salud, Junta de Andalucía, Mahidol University, University of Belgrade, Vinča Institute of Nuclear Sciences, Valencian International University
Language: English
Subfield: Molecular Medicine
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $7,990
Awards: G1151860386, G1175115578, G1855990336, G192034502, G2262748287, G2309174360, G2585926585, G2718006529, G279363373, G2875779252, G2892333189, G300979063, G34346518, G3480869486, G410571670, G4154214804, G425668148, G430777504, G451917667, G5080475149, G5421974903, G5636076946, G586857820, G5967599077, G7313991775, G7391727506, G8920660035, G929308097, G99296377
OpenAlex ID: W4415729450